Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Rigel Pharmaceuticals, Inc. (RIGL) had Revenue of $101.69M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$101.69M
Net Income	$59.61M
Cost of Goods Sold	$4.50M
Gross Profit	$97.18M
Operating Expenses	$40.58M
Operating Income	$61.10M
Non-Operating Income/Expense	$-1.12M
Pre-Tax Income	$59.98M
Normalized Pre-Tax Income	$59.98M
Income after Taxes	$59.61M
Income from Continuous Operations	$59.61M
Consolidated Net Income/Loss	$59.61M
Normalized Income after Taxes	$59.61M
EBIT	$61.10M
EBITDA	$61.46M
Weighted-Average Shares Outstanding (Basic)	17.89M
Weighted-Average Shares Outstanding (Diluted)	18.16M
Earnings per Share (EPS) (Basic)	$3.33
Earnings per Share (EPS) (Diluted)	$3.28
Balance Sheet Financials
Current Assets	$175.39M
Property, Plant, and Equipment	$0.06M
Long-Term Assets	$31.34M
Total Assets	$206.74M
Current Liabilities	$86.64M
Long-Term Debt	$37.45M
Long-Term Liabilities	$38.17M
Total Liabilities	$124.80M
Common Equity	$81.93M
Tangible Shareholders Equity	$56.01M
Shareholders Equity	$81.93M
Common Shares Outstanding	17.94M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$29.64M
Cash Flow from Investing Activities	$-33.83M
Cash Flow from Financial Activities	$0.90M
Beginning Cash	$56.75M
End Cash	$53.46M
Increase/Decrease in Cash	$-3.28M
Stock-Based Compensation	$6.60M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.02
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.31
Debt to Equity Ratio	0.73
Gross Margin	95.57%
Operating Margin	60.09%
EBIT Margin	60.09%
EBITDA Margin	--
Pre-Tax Profit Margin	58.99%
Profit Margin	58.63%
Free Cash Flow	$29.64M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.49
Inventory Turnover	0.43
Receiveable Turnover	2.55
Days Sales in Receivables	35.32
Return on Equity	72.76%
Return on Tangible Equity	106.43%
Return on Assets	28.84%
Return on Investments	49.93%
Book Value Per Share	$4.57
Free Cash Flow per Share	$1.63
Operating Cash Flow per Share	$1.63

Data from Zacks Investment Research, Inc.